The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! The stock decreased 4.76% or $0.45 during the last trading session, hitting $9. About 1.22M shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 55.43% since April 27, 2016 and is uptrending. It has outperformed by 50.20% the S&P500.
The move comes after 7 months negative chart setup for the $251.67 million company. It was reported on Nov, 30 by Barchart.com. We have $8.19 PT which if reached, will make NASDAQ:CARA worth $22.65 million less.
Analysts await Cara Therapeutics Inc (NASDAQ:CARA) to report earnings on March, 9. They expect $-0.51 EPS, down 45.71% or $0.16 from last year’s $-0.35 per share. After $-0.42 actual EPS reported by Cara Therapeutics Inc for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.
Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage
Out of 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 7 analyst reports since July 27, 2015 according to StockzIntelligence Inc. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald. Needham maintained it with “Buy” rating and $27 target price in Friday, July 24 report. The company was maintained on Thursday, November 24 by Scotia Capital. H.C. Wainwright initiated Cara Therapeutics Inc (NASDAQ:CARA) on Thursday, October 13 with “Buy” rating.
According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”
Insitutional Activity: The institutional sentiment increased to 1.83 in 2016 Q2. Its up 1.13, from 0.7 in 2016Q1. The ratio improved, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Blackrock Institutional Na holds 0% or 416,785 shares in its portfolio. Franklin Resources Inc holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 611,400 shares. Cam Group Holdings A S holds 268,000 shares or 0.02% of its portfolio. Bridgeway Mgmt accumulated 0.01% or 131,646 shares. Ny State Common Retirement Fund last reported 19,600 shares in the company. Baldwin Brothers Ma owns 39,354 shares or 0.04% of their US portfolio. Tudor Invest Et Al owns 44,763 shares or 0% of their US portfolio. Susquehanna Intll Grp Inc Llp has invested 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Deutsche Bankshares Ag has 12,662 shares for 0% of their US portfolio. Manufacturers Life Ins The, a Ontario – Canada-based fund reported 807 shares. Aqr Limited Liability Company, a Connecticut-based fund reported 157,057 shares. Royal Comml Bank Of Canada holds 955 shares or 0% of its portfolio. The North Carolina-based Bank & Trust Of America De has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Bnp Paribas Arbitrage last reported 789 shares in the company. Blackrock Advisors Limited Liability Company, a Delaware-based fund reported 69,398 shares.
CARA Company Profile
Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.